Patents by Inventor Hongyue Dai
Hongyue Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220112562Abstract: Prognostic and predictive biomarkers are disclosed that can be used in systems and methods for predicting the prognosis of a subject with a cancer and to direct therapy based on that prognosis.Type: ApplicationFiled: June 2, 2021Publication date: April 14, 2022Inventor: Hongyue A. Dai
-
Publication number: 20180305768Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.Type: ApplicationFiled: March 1, 2018Publication date: October 25, 2018Applicants: The Netherlands Cancer Institute, Merck Sharp & Dohme Corp.Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
-
Patent number: 9909185Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.Type: GrantFiled: October 19, 2012Date of Patent: March 6, 2018Assignees: THE NETHERLANDS CANCER INSTITUTE, MERCK SHARP & DOHME CORP.Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
-
Publication number: 20170298443Abstract: Prognostic and predictive biomarkers are disclosed that can be used in systems and methods for predicting the prognosis of a subject with a cancer and to direct therapy based on that prognosis.Type: ApplicationFiled: September 24, 2015Publication date: October 19, 2017Inventor: Hongyue A. Dai
-
Patent number: 8744778Abstract: In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.Type: GrantFiled: August 12, 2011Date of Patent: June 3, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Yejun Tan, Hongyue Dai, Pek Yee Lum, John Ryan Thompson, Joel Peter Berger, Eric Stanley Muise, Richard F. Raubertas, Kenny Kin Chung Wong
-
Publication number: 20140030255Abstract: In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting whether a subject with cancer will respond to treatment with an agent, based on whether the cancer is classified as having a high or low EMT Signature Score.Type: ApplicationFiled: November 2, 2011Publication date: January 30, 2014Applicant: MERCK SHARP & DOHME CORP.Inventors: Andrey Loboda, Michael Nebozhyn, Hongyue Dai
-
Publication number: 20140031251Abstract: In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting cancer patient prognosis based on whether the cancer is classified as having a high or low EMT Signature Score.Type: ApplicationFiled: November 2, 2011Publication date: January 30, 2014Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Merck Sharp & Dohme Corp.Inventors: Timothy Yeatman, Andrey Loboda, Michael Nebozhyn, Hongyue Dai
-
Patent number: 8521441Abstract: A method for fluorophore bias removal in microarray experiments in which the fluorophores used in microarray experiment pairs are reversed. Further, a method for calculating the individual errors associated with each measurement made in nominally repeated microarray experiments. This error measurement is optionally coupled with rank based methods in order to determine a probability that a cellular constituent is up or down regulated in response to a perturbation. Finally, a method for determining the confidence in the weighted average of the expression level of a cellular constituent in nominally repeated microarray experiments.Type: GrantFiled: January 24, 2005Date of Patent: August 27, 2013Assignee: Microsoft CorporationInventors: Roland Stoughton, Hongyue Dai
-
Patent number: 8447526Abstract: The present invention provides methods and computer programs for detecting variations in measurements of a biological variable, e.g., variations in cell viability, under different conditions, e.g., with or without treatment of a drug, under the treatments of different drugs, or under different environmental conditions. The methods and programs of the invention determine a metric of difference between measurements under different condition, and make use of predetermined errors of the measurements, e.g., errors determined from an error model, to estimate the errors in the metric of difference. Such an approach provides a more accurate estimate of the errors of measurements, which, in turn, provides a more accurate estimate of the error of the difference metric.Type: GrantFiled: May 23, 2006Date of Patent: May 21, 2013Assignee: Microsoft CorporationInventors: Lee Weng, Hongyue Dai, Steven R. Bartz
-
Publication number: 20120072124Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.Type: ApplicationFiled: August 10, 2011Publication date: March 22, 2012Inventors: Jerald P. Radich, Hongyue Dai, Mao Mao, Janell M. Schelter, Peter S. Linsley
-
Patent number: 8105777Abstract: The present invention relates to genetic markers whose expression is correlated with colon cancer. In one aspect, the invention provides sets of markers whose expression can be used for classifying colon cancer patients into different prognostic categories. In another aspect, the invention provides kits containing marker sets for determining prognosis of colon cancer. In another aspect, the invention provides methods of classifying cancer patients with regard to prognosis.Type: GrantFiled: February 12, 2009Date of Patent: January 31, 2012Assignees: Nederlands Kanker Instituut, Merck Sharp & Dohme Corp.Inventors: Hongyue Dai, Laura J. Van't Veer, Yudong He
-
Publication number: 20110301048Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.Type: ApplicationFiled: November 23, 2010Publication date: December 8, 2011Applicants: MERCK SHARP & DOHME CORP., THE NETHERLANDS CANCER INSTITUTEInventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
-
Publication number: 20110294696Abstract: In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.Type: ApplicationFiled: August 12, 2011Publication date: December 1, 2011Applicant: MERCK SHARP & DOHME CORP.Inventors: Yejun Tan, Hongyue Dai, Pek Yee Lum, John Ryan Thompson, Joel Peter Berger, Eric Stanley Muise, Richard F. Raubertas, Kenny Kin Chung Wong
-
Patent number: 8019552Abstract: The present invention provides prognostic methods for conditions such as cancer, for example, breast cancer, comprising classifying an individual by a plurality of phenotypic, genotypic or clinical characteristics of the condition into a plurality of patient subsets, and analyzing the pattern of expression of prognosis-informative genes identified for that subset in a sample from the individual. The present invention also provides methods for constructing such patient subsets and of identifying prognosis-informative genesets for such subsets. The invention further provides methods of assigning a therapeutic regimen to an individual, microarrays useful for performing prognosis, kits comprising these microarrays, and computer systems and programs for implementing the methods of the invention.Type: GrantFiled: March 7, 2005Date of Patent: September 13, 2011Assignees: The Netherlands Cancer Institute, Merck Sharp & Dohme Corp.Inventors: Hongyue Dai, Laura J. Van't Veer, John Lamb, Roland Stoughton, Stephen H. Friend, Yudong He
-
Patent number: 8014957Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.Type: GrantFiled: December 14, 2006Date of Patent: September 6, 2011Assignees: Fred Hutchinson Cancer Research Center, Rosetta Inpharmatics LLCInventors: Jerald P. Radich, Hongyue Dai, Mao Mao, Janell M. Schelter, Peter S. Linsley
-
Patent number: 8014954Abstract: In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.Type: GrantFiled: April 4, 2006Date of Patent: September 6, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Yejun Tan, Hongyue Dai, Pek Yee Lum, John Ryan Thompson, Joel Peter Berger, Eric Stanley Muise, Richard F Raubertas, Kenny Kin Chung Wong
-
Publication number: 20110166200Abstract: The present invention provides compositions and methods for predicting the hypoxia response in tumor cells, methods for predicting the likelihood of cancer metastasis, and methods for inhibiting tumor cell proliferation using a microRNA comprising miR-210.Type: ApplicationFiled: April 16, 2009Publication date: July 7, 2011Inventors: Zhan Zhang, Sun Hong, Hongyue Dai, Jan Schelter, Julia Burchard, Xudong Dai, Michael Carleton, Michael Cleary, Peter Linsley, Carla Grandori
-
Patent number: 7966130Abstract: A method for fluorophore bias removal in microarray experiments in which the fluorophores used in microarray experiment pairs are reversed. Further, a method for calculating the individual errors associated with each measurement made in nominally repeated microarray experiments. This error measurement is optionally coupled with rank based methods in order to determine a probability that a cellular constituent is up or down regulated in response to a perturbation. Finally, a method for determining the confidence in the weighted average of the expression level of a cellular constituent in nominally repeated microarray experiments.Type: GrantFiled: November 4, 2002Date of Patent: June 21, 2011Assignee: Microsoft CorporationInventors: Roland Stoughton, Hongyue Dai
-
Patent number: 7863001Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.Type: GrantFiled: June 23, 2008Date of Patent: January 4, 2011Assignees: The Netherlands Cancer Institute, Merck Sharp & Dohme Corp.Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, Augustinus A. M. Hart
-
Publication number: 20100284915Abstract: The invention provides molecular markers that are associated with responsiveness of a cancer patient to a chemotherapy treatment, and methods and computer systems for determining such responsiveness based on measurements of these molecular markers. The present invention also provides methods and compositions for enhancing the efficacy of chemotherapies in patients by modulating the expression or activity of genes encoding these molecular markers and/or their encoded proteins.Type: ApplicationFiled: June 28, 2007Publication date: November 11, 2010Inventors: Hongyue Dai, Chunsheng Zhang, Andrey Loboda